Skip to main content
OpenTrials
Completed

NCT Number: NCT02832557

A Salivary miRNA Diagnostic Test for Autism

The goal of this study is to validate a panel of miRNAs that distinguish children with autism spectrum disorder (ASD) from their non-ASD peers with a positive MCHAT-R. These biomarkers may allow earlier diagnosis of autism, allowing earlier service, and also help us to understand some of the changes in the brains of autistic children.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The central aim of this project is to validate a panel of expressed microRNA (miRNA) in the saliva of children identified at risk for developing ASD by the MCHAT-R. Further, this study aims to assess the value of the current panel as an adjunctive test that may increase specificity of MCHAT-R positive results, or affirm clinical diagnoses alongside the ADOS or other objective assessments.

The primary endpoints of this study are as follows:

  • Evaluate the diagnostic ability (sensitivity and specificity) of the current a salivary microtranscriptome panel for distinguishing children with ASD from their non-ASD peers.
  • Assess stability of the salivary microtranscriptome diagnosis over time, and interrogate longitudinal microtranscriptome levels relative to neuropsychological measures.

Secondary endpoints are the identification of microtranscriptome features whose concentrations correlate with ASD endophenotypes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age at enrollment: 24 months to 48 months (inclusive)
  • MCHAT-R score of 3 or greater
  • Parent/guardian must be fluent in spoken English (required to complete study specific questionnaires etc)

Exclusion criteria

  • confounding neurological (i.e. cerebral palsy, epilepsy), sensory (i.e. auditory or visual) impairments, and feeding tube dependence.
  • history of extreme pre-term birth (< 32 weeks gestation)
  • wards of the state
  • Autistic subjects with known syndromic autism (attributed to a known genetic mutation)

Treatment and study plan

Salivary collection

Other

Collection of saliva via swab for miRNA processing

Vineland Adaptive Behavior Scale-III Assessment

Other

Medical history questionaire

Other

Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)

Other

Mullen Scales of Early Learning

Other

Primary outcomes

  1. Salivary miRNA profile

    Time frame: at the time of collect (from 18m to 6 years of age)

    Measures of miRNA abundance in saliva

Secondary outcomes

  1. Measures of adaptive function

    Time frame: At time of enrollment (from 18m to 6 years of age)

    Vineland Adaptive Behavior Composite Score

  2. Measures of early intellectual development

    Time frame: At time of enrollment (from 18m to 6 years of age)

    Mullen Scales of Early Learning

  3. Measure of autistic behavior

    Time frame: At time of enrollment (from 18m to 6 years of age)

    Autism Diagnostic Observation Schedule (ADOS) Composite Score (Autism Group Only)

Sponsors and collaborators

Lead sponsor

State University of New York - Upstate Medical University

Other

Collaborators

  • Baylor College of Medicine
  • Children's Hospital Medical Center, Cincinnati
  • Milton S. Hershey Medical Center
  • National Institute of Mental Health (NIMH)
  • Quadrant Biosciences Inc.
  • University of Missouri-Columbia

Registry information

Official study title

Validation of a Salivary miRNA Diagnostic Test for Autism Spectrum Disorder

Important dates

Study start
2015
Primary completion
2021
Study completion
2021
First posted
Jul 14, 2016
Registry last updated
Jun 5, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.